terican

Last verified · v1.0

Calculator · health

Apri (Ast To Platelet Ratio Index) Calculator

The APRI Calculator estimates liver fibrosis and cirrhosis risk using AST levels and platelet count — a non-invasive, WHO-endorsed screening tool.

FreeInstantNo signupOpen source

Inputs

APRI Score

—

Explain my result

0/3 free

Get a plain-English breakdown of your result with practical next steps.

APRI Score—

The formula

How the
result is
computed.

What Is the APRI Score?

The AST to Platelet Ratio Index (APRI) is a non-invasive scoring tool that estimates the degree of hepatic fibrosis and cirrhosis in patients with chronic liver disease. Developed by Wai et al. in 2003 and validated across multiple independent cohorts, the APRI score requires only two routine blood test values — serum aspartate aminotransferase (AST) and platelet count — making it one of the most cost-effective and widely accessible liver fibrosis markers in clinical use. The selection of these two specific parameters reflects fundamental pathophysiologic principles: elevated AST directly indicates active hepatocellular injury, while thrombocytopenia is a highly sensitive indicator of portal hypertension and advancing hepatic fibrosis.

The World Health Organization (WHO) endorses APRI as a preferred non-invasive fibrosis test in resource-limited settings, particularly for staging liver disease in persons living with chronic hepatitis C and hepatitis B. This endorsement is documented in the WHO Guidelines for Screening, Care and Treatment of Persons with Chronic Hepatitis C Infection.

The APRI Formula

The APRI score is calculated using the following formula:

APRI = [(AST ÷ ASTULN) ÷ Platelet Count (×109/L)] × 100

The result is a dimensionless ratio scaled by 100. A higher score reflects greater hepatocellular injury relative to platelet count — both hallmarks of advancing fibrosis and portal hypertension. The mathematical structure of the APRI formula elegantly captures the inverse relationship between transaminase elevation and platelet count, as both markers worsen with progressive fibrosis.

Variables Defined

  • AST (Aspartate Aminotransferase): A liver enzyme measured in U/L (units per liter). Elevated AST levels indicate hepatocellular damage. The typical adult reference range is 10–40 U/L, though this varies by laboratory and patient sex.
  • AST ULN (Upper Limit of Normal): The laboratory-specific upper reference limit for AST. Accurate APRI calculation depends on using the correct lab-specific ULN. The most commonly used value is 40 U/L; some laboratories report 35 or 37 U/L.
  • Platelet Count: Expressed in 109/L, equivalent to K/µL or 1,000/µL. Normal platelet counts range from 150–400 × 109/L. Thrombocytopenia is a recognized marker of portal hypertension and advanced hepatic fibrosis.

How to Interpret APRI Results

Clinical validation studies have established the following APRI thresholds for diagnosing significant fibrosis (Metavir ≥ F2) and cirrhosis (Metavir F4), as referenced in the University of Washington Hepatitis C Online APRI Calculator and Hepatitis B Online APRI Calculator. These thresholds have been extensively validated in prospective multicenter cohorts and are recommended by major hepatology societies worldwide.

  • APRI < 0.5: Significant fibrosis is unlikely. Studies report a negative predictive value (NPV) approaching 90% at this threshold.
  • APRI 0.5 – 1.5: Indeterminate zone. Additional diagnostic testing — such as transient elastography (FibroScan) or liver biopsy — may be required.
  • APRI > 1.5: Significant fibrosis is likely. The positive predictive value (PPV) is approximately 88% in hepatitis C populations.
  • APRI ≥ 2.0: Cirrhosis is likely. The WHO employs this threshold in its hepatitis C treatment guidelines for predicting advanced fibrosis.

Worked Example

A 48-year-old patient with chronic hepatitis C presents with the following laboratory values: AST = 72 U/L, laboratory AST ULN = 40 U/L, platelet count = 120 × 109/L.

Calculation: APRI = (72 ÷ 40) ÷ 120 × 100 = 1.80 ÷ 120 × 100 = 1.50

An APRI of 1.50 sits at the upper boundary of the indeterminate zone, suggesting clinically significant fibrosis is plausible. This result warrants further evaluation through elastography or guided liver biopsy.

Beyond Hepatitis: Emerging Applications

While originally validated in hepatitis C populations, the APRI score has demonstrated utility across multiple etiologies, including hepatitis B, non-alcoholic fatty liver disease (NAFLD), and alcoholic liver disease. Research published in PMC (2023) also investigated AST/ALT-to-platelet ratio indices as potential predictors of gynecological malignancies, underscoring the broader prognostic applications of platelet-indexed liver enzyme ratios.

Limitations

  • AST elevation from non-hepatic sources (e.g., myocardial infarction, skeletal muscle injury, hemolysis) can falsely elevate the APRI score.
  • Hematological conditions causing thrombocytopenia or thrombocytosis independently alter the platelet-based denominator.
  • APRI shows reduced diagnostic accuracy in HIV co-infected patients and during acute hepatitis B flares.
  • The indeterminate zone (APRI 0.5–1.5) accounts for a substantial proportion of patients and does not provide actionable staging without further investigation.
  • Clinicians must recognize these limitations when interpreting APRI results to avoid inappropriate treatment recommendations and ensure appropriate patient counseling.

Reference

Frequently asked questions

What is a normal APRI score?
An APRI score below 0.5 is generally considered normal and suggests significant liver fibrosis is unlikely, with a negative predictive value close to 90%. For example, a patient with AST of 35 U/L (ULN 40) and platelets of 200 × 10⁹/L yields an APRI of 0.44 — well within the low-risk range and typically requiring no further fibrosis workup.
What does an APRI score above 2.0 mean?
An APRI score of 2.0 or higher indicates a high likelihood of cirrhosis. The WHO uses this threshold in its hepatitis C treatment guidelines to identify patients with advanced hepatic fibrosis. For example, a patient with AST = 85 U/L (ULN 40) and platelets = 90 × 10⁹/L yields an APRI of approximately 2.36, placing them firmly in the cirrhosis-likely category and prompting urgent hepatology referral.
What AST upper limit of normal (ULN) should be used in the APRI calculator?
The AST ULN should match the reference range reported by the patient's specific laboratory. The most commonly used value is 40 U/L, but some laboratories use 35 or 37 U/L. Using an incorrect ULN can meaningfully alter the APRI result and lead to misclassification. Always check the reference range printed on the lab report rather than assuming a universal standard value.
How does APRI compare to the FIB-4 index for assessing liver fibrosis?
Both APRI and FIB-4 are non-invasive, blood-test-based fibrosis scores. FIB-4 incorporates age, ALT, AST, and platelet count and generally shows higher diagnostic accuracy for advanced fibrosis, particularly in NAFLD patients. APRI requires fewer inputs and is recommended by the WHO for resource-limited settings. Using both scores together improves diagnostic confidence when results are concordant, reducing the need for liver biopsy.
Can the APRI calculator be used for non-alcoholic fatty liver disease (NAFLD)?
Yes, APRI has been evaluated in NAFLD populations, though its diagnostic performance is somewhat lower than in hepatitis C cohorts. Studies report moderate sensitivity and specificity for advanced fibrosis in NAFLD at the standard 0.5 and 1.5 thresholds. Clinicians often use APRI alongside other non-invasive markers like FIB-4 or transient elastography when comprehensively assessing fibrosis severity in NAFLD patients.
What can cause a falsely elevated APRI score?
AST elevations from non-hepatic sources — including acute myocardial infarction, rhabdomyolysis, hemolysis, or intense physical exercise — can produce falsely high APRI values. Thrombocytopenia arising from causes unrelated to portal hypertension, such as immune thrombocytopenic purpura, bone marrow disorders, or chemotherapy, can also artificially inflate the score. Clinicians must always interpret APRI results within the full clinical and laboratory context.